GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
May 03, 2024 07:00 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1...
Pacific Clinics Announces 100 Job Openings in Bay Area
April 25, 2024 16:42 ET
|
Pacific Clinics
Campbell, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Pacific Clinics, California’s leading provider of community-based mental health and substance use services, has more than 100 open job positions...
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
April 23, 2024 08:15 ET
|
Silo Pharma, Inc.
Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”),...
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
April 17, 2024 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those...
Enhancing Positive Emotions to Prevent Depression in Youth - A Free Webinar from the Brain & Behavior Research Foundation
April 02, 2024 10:30 ET
|
Brain & Behavior Research Foundation
New York, April 02, 2024 (GLOBE NEWSWIRE) -- The CDC has reported alarming rates of depression among America’s youth, with 42% of high school students feeling so sad or hopeless almost every day for...
Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region
March 13, 2024 14:13 ET
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution...
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
February 29, 2024 07:00 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024Phase 2a clinical trial of GH001 in postpartum...
FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with StimGuide Pro
January 30, 2024 09:18 ET
|
Magstim EGI
FDA clears Magstim TMS System Horizon 3.0 with StimGuide Pro providing treatment for patients patients with depressive or obsessive-compulsive conditions
United Kingdom Mental Health Apps Market Size, Share & Trends Analysis Report 2023-2030 Featuring Mindspace, Calm, Headspace, Youper, MoodMission, and Sanvello Health
January 24, 2024 10:27 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "U.K. Mental Health Apps Market Size, Share & Trends Analysis Report By Platform (Android, iOS), By Application (Depression & Anxiety...
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
January 18, 2024 16:30 ET
|
GH Research PLC
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...